Bristol-Myers Squibb (BMY) is back on many investors’ radar after recent share price moves and fresh scrutiny of its fundamentals, including revenue of US$48.0b and net income of US$6.0b.

Bristol-Myers Squibb’s share price is US$54.28, with a 90 day share price return of 17.82% compared with a 1 year total shareholder return decline of 3.58%, suggesting recent momentum after a weaker period for holders.

If recent moves in big pharma have your attention, it could be a useful moment to scan other pharma stocks with solid dividends that might fit your income and quality checklist.

With Bristol-Myers Squibb trading at US$54.28 and flagged with a sizeable intrinsic discount estimate, the key question is whether this represents genuine undervaluation or a price that already reflects future growth expectations.

Most Popular Narrative: 3.5% Undervalued

At a last close of $54.28 versus a narrative fair value of $56.26, Bristol-Myers Squibb is framed as modestly undervalued, with that gap hinging on specific pipeline and earnings assumptions.

Robust late-stage pipeline and ongoing life-cycle management for major brands, plus partnerships, expand the breadth of future regulatory approvals and label expansions, increasing the likelihood of incremental indications and reimbursement in additional markets. This in turn is expected to help offset upcoming patent expiries and competitive threats, while providing a more diversified earnings base and smoother long-term growth profile.

Curious what kind of revenue reset, margin lift, and future P/E level are baked into that fair value? The narrative leans on detailed earnings bridges, patent cliff offsets, and a tight band of analyst profit scenarios that could shift the whole picture.

Result: Fair Value of $56.26 (UNDERVALUED)

However, that story can change quickly if key patent expiries hit harder than expected or if major late stage trials fail to deliver the hoped for approvals.

Build Your Own Bristol-Myers Squibb Narrative

If you read this and think the assumptions do not quite match your view, you can pull up the same data, stress test your own expectations, and build a personalised Bristol Myers Squibb story in just a few minutes with Do it your way.

A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you stop with just one company, you could miss out on other stocks that match your goals, so put the Screener to work for your watchlist today.

• Spot potential mispricing by scanning these 869 undervalued stocks based on cash flows that line up with your preferred balance of quality, cash flows, and long term opportunity.
• Tap into growth themes by checking out these 24 AI penny stocks that are tied to real business models rather than just hype.
• Strengthen your income focus by reviewing these 14 dividend stocks with yields > 3% that combine higher yields with fundamental checks you can compare side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.